Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

AGM Statement

28 Apr 2005 07:00

Torex Retail PLC28 April 2005 Torex Retail Plc AGM Statement Torex Retail Plc ("Torex Retail" or "the Group"), the UK's market leader inretail IT solutions, will today hold its inaugural Annual General Meeting. RobLoosemore, Chairman, will comment on current trading as follows: "Torex Retail performed strongly in 2004 and the momentum developed during lastyear has been carried forward into 2005. We are pleased to report that tradingto date is in line with our expectations and, with buoyant market conditions anda high level of revenue visibility, the Board remain confident of both our fullyear forecasts and the future growth prospects for the Group. In addition, we are delighted with the progress made by the Alphameric RetailDivision (ARD), which was acquired in November 2004, and which continues totrade in line with our expectations. This reflects new business wins (AnnTaylor and Littlewoods) for our Smartdecision merchandise planning product,coupled with decisive action taken to reduce the cost base. The division is nowfully integrated into the Torex Retail business." Other highlights include: • First installations of Lucas into the UK: Following the successful launch in the UK of Lucas, our market leading Java EPOS solution, installations have already been completed with Esprit, Deichmann shoe stores and a major regional department store. Further announcements are expected shortly. • Cross selling of Lucas is ahead of schedule. The very strong demand for Lucas from the former ARD customer base has resulted in a number of early contract wins, including JD Sports with installations into their 68 UK stores planned for the next quarter. In addition, Lucas has already been installed in Reiss' flagship New York store and Nora O'Connell stores in Ireland. Chris Moore, Chief Executive, comments: "I am delighted with the start we have made to the year. Most encouraging hasbeen the new contract wins for Lucas, in particular, the deal with JD Sports inthe face of stiff competition. This win, together with the UK Lucas sales, willprovide valuable reference sites from which to leverage Lucas further into theUK market. The outlook for the full year remains very positive." It is expected that the Group's interim results for the six months ending 30June, 2005 will be announced in mid September 2005. Enquiries: Torex Retail 0870 050 9900 Rob Loosemoore, Chairman / Richard Thompson, FD Citigate Dewe Rogerson 020 7638 9571 Ginny Pulbrook / Sebastian Hoyle / Lucie Holloway This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Nov 20249:32 amRNSForm 8.3 - Tissue Regenix Group Plc
12th Nov 20244:05 pmRNSForm 8 (OPD) (Tissue Regenix Group Plc)
12th Nov 20248:46 amRNSForm 8.5 (EPT/NON-RI)
11th Nov 20249:17 amRNSForm 8.5 (EPT/NON-RI)
7th Nov 20249:59 amRNSForm 8.5 (EPT/NON-RI) - Tissue Regenix Group PLC
6th Nov 20241:37 pmRNSForm 8.3 - Tissue Regenix Group PLC
6th Nov 20248:52 amRNSForm 8.5 (EPT/NON-RI)
5th Nov 20242:24 pmRNSForm 8.3 - Tissue Regenix Group PLC
5th Nov 202411:32 amRNSForm 8.5 (EPT/NON-RI)
4th Nov 20244:36 pmRNSResponse to media speculation
10th Sep 20247:00 amRNSInterim results for the six months ended 30 June
18th Jul 20243:52 pmRNSGrant of share options
16th Jul 20247:00 amRNSHalf-Year Trading Update
3rd Jul 20241:16 pmRNSHolding(s) in Company
24th Jun 20244:12 pmRNSHolding(s) in Company
18th Jun 20245:15 pmRNSExercise of Options, Director Dealing and TVR
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.